Results 21 to 30 of about 22,201 (271)

Trajectory and progress of opioid agonist therapy programs in the Kyrgyz Republic. [PDF]

Glob Health Econ Sustain
The incidence and mortality of human immunodeficiency viruses (HIVs) are rising in Eastern Europe and Central Asia (EECA), particularly among people who inject drugs. Opioid agonist therapies (OATs), such as methadone or buprenorphine, are the most effective treatments for opioid use disorder and serve as a key HIV-prevention strategy in EECA.
Liberman AR, Kurmanalieva A, Biibosunova DI, Shumskaya N, Ivasiy R, Bromberg DJ, Madden LM, Altice FL.   +7 more
europepmc   +3 more sources

Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy [PDF]

Drug and Alcohol Dependence, 2016
In a sample of patients receiving opioid agonist therapy, we evaluated whether having chronic pain was associated with (a) craving for opioids and (b) illicit opioid use.In a cross-sectional study of adults on buprenorphine or methadone maintenance recruited from an urban medical center, we examined any craving for opioids (primary dependent variable ...
Judith I Tsui, Marlene C Lira, Debbie M Cheng   +2 more
exaly   +3 more sources

The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia. [PDF]

Clin Infect Dis
Abstract Background People prescribed opioid agonist therapy (OAT) are a key population for hepatitis C virus (HCV) elimination. Health service engagement associated with OAT provision may facilitate hepatitis C testing and treatment.
Griffin S, Asselin J, Wilkinson AL, Traeger MW, Pedrana A, Winter RJ, Thompson AJ, Penn M, Dimech W, Donovan B, Hellard M, Stoové M.   +11 more
europepmc   +3 more sources

Federal opioid agonist therapy policy: interrupted time series analysis of the impact of the methadone exemption removal across eight provinces in Canada [PDF]

BMC Health Services Research
Background Federal deregulation of opioid agonist therapies are an attractive policy option to improve access to opioid use disorder care and achieve widespread beneficial impacts on growing opioid-related harms.
Abhimanyu Sud, Chloe Campbell, Arani Sivakumar, Ross Upshur, Rahim Moineddin, Kellia Chiu   +5 more
doaj   +2 more sources

Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver, Canada [PDF]

Drug and Alcohol Dependence, 2018
Inability to access opioid agonist therapy (OAT) in correctional settings has previously been reported in Vancouver, Canada, and is associated with harms among people with opioid use disorder (OUD), including overdose death. We investigated the prevalence and correlates of OAT utilization within correctional settings among incarcerated persons with OUD
Nikki Bozinoff, Kora Debeck, M-J Milloy   +2 more
exaly   +3 more sources

Multimethod feasibility evaluation of smoking cessation intervention for patients receiving opioid agonist therapy [PDF]

Pilot and Feasibility Studies
Background Among patients receiving opioid agonist therapy, 85% are active tobacco smokers. Despite the significant impact of smoking-related pulmonary diseases on disability and mortality in this population, less than 10% successfully quit smoking with ...
Karl Trygve Druckrey-Fiskaaen, Tesfaye Madebo, Siv-Elin Leirvåg Carlsen, Einar Furulund, Jørn Henrik Vold, Jan Tore Daltveit, Torgeir Gilje Lid, Lars T. Fadnes, ATLAS4LAR Study Group   +8 more
doaj   +2 more sources

Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management

Molecules, 2020
Opioid analgesics are effective pain therapeutics but they cause various adverse effects and addiction. For safer pain therapy, biased opioid agonists selectively target distinct μ opioid receptor (MOR) conformations, while the potential of biased opioid
Wolfgang Sadee, John Oberdick, Zaijie Wang   +2 more
doaj   +2 more sources

Barriers and facilitators for family physicians prescribing opioid agonist therapy in Saskatchewan. [PDF]

Can Fam Physician
To explore barriers and facilitators for family physicians in Saskatchewan prescribing opioid agonist therapy (OAT).Self-administered postal survey.Family medicine practices in Saskatchewan.A total of 218 Saskatchewan family physicians who were not authorized to prescribe OAT as of June 2022.Descriptive and inferential statistics of physicians' self ...
Nguyen T, Bareham J, Halpape K.
europepmc   +3 more sources

Advances in the delivery of buprenorphine for opioid dependence

Drug Design, Development and Therapy, 2017
Richard N Rosenthal,1 Viral V Goradia2 1Department of Psychiatry, Addiction Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, 2Department of Psychiatry, Upstate Medical University, Syracuse, NY, USA Abstract: Opioid use ...
Rosenthal RN, Goradia VV
doaj   +1 more source

Exploring the role of urine drug screening in opioid agonist therapy. [PDF]

Med J Aust
FitzGerald G, Crawford S, Dunlop AJ, Cook J, Membrey D, MacCartney P, Naren T.   +6 more
europepmc   +3 more sources